Keyword Analysis & Research: akcea
Keyword Research: People who searched akcea also searched
Search Results related to akcea on Search Engine
-
About Akcea | Ionis Pharmaceuticals, Inc.
https://www.ionispharma.com/akcea/about-akcea/
WEBAbout Akcea. Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. Akcea commercializes TEGSEDI ® (inotersen) and WAYLIVRA ® (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis’ proprietary …
DA: 47 PA: 17 MOZ Rank: 65
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
https://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-completes-acquisition-akcea-therapeutics
WEBSep 14, 2020 · CARLSBAD, Calif., Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better …
DA: 73 PA: 40 MOZ Rank: 68
-
Ionis Pharmaceuticals completes acquisition of Akcea ... - BioSpace
https://www.biospace.com/article/releases/ionis-pharmaceuticals-completes-acquisition-of-akcea-therapeutics/
WEBOct 12, 2020 · The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing value to all stakeholders. Under the terms of the definitive agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock. As a result of the …
DA: 11 PA: 16 MOZ Rank: 67
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea …
https://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-acquire-remaining-stake-akcea-therapeutics
WEBAugust 31, 2020 at 6:55 AM EDT. - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash- Transaction drives efficiencies, enhances capabilities and further strengthens Ionis' financial position- Transaction is a key step in the evolution of Ionis' business strategy.
DA: 1 PA: 97 MOZ Rank: 37
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-completes-acquisition-of-akcea-therapeutics-301150205.html
WEBOct 12, 2020 · The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing value to all stakeholders. Under the...
DA: 100 PA: 67 MOZ Rank: 12
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-acquire-remaining-stake-in-akcea-therapeutics-301120837.html
WEBAug 31, 2020 · CARLSBAD, Calif. and BOSTON, Aug. 31, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have...
DA: 83 PA: 53 MOZ Rank: 42
-
Akcea and Ionis Receive FDA Approval of TEGSEDI™ …
https://ir.ionispharma.com/news-releases/news-release-details/akcea-and-ionis-receive-fda-approval-tegseditm-inotersen
WEBOct 5, 2018 · BOSTON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the U.S. Food and Drug Administration (FDA) has approved TEGSEDI TM (inotersen) for the treatment of …
DA: 3 PA: 83 MOZ Rank: 42
-
Akcea and Pfizer Inc. Announce Licensing Agreement for …
https://www.pfizer.com/news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx
WEBOct 7, 2019 · Akcea will settle its $125 million obligation to Ionis in Akcea common stock. The companies are also eligible to receive development, regulatory and sales milestone payments of up to $1.3 billion and tiered, double-digit royalties on annual worldwide net sales following marketing approval of AKCEA-ANGPTL3-LRx.
DA: 15 PA: 53 MOZ Rank: 20
-
Ionis agrees to take remaining stake in Akcea Therapeutics for …
https://www.pharmaceutical-technology.com/news/ionis-acquires-akcea/
WEBSep 1, 2020 · Akcea is a biopharmaceutical firm that develops and commercialises drugs to treat patients with serious and rare diseases. The company is currently commercialising Tegsedi (inotersen) and Waylivra (volanesorsen). Its pipeline includes AKCEA-APO (a)-L, vupanorsen (AKCEA-ANGPTL3-L), AKCEA-APOCIII-L and AKCEA-TTR-L.
DA: 66 PA: 50 MOZ Rank: 45
-
Ionis strikes deal to buy back lipid disease spinout Akcea
https://www.fiercebiotech.com/biotech/ionis-strikes-deal-to-buy-back-lipid-disease-spinout-akcea
WEBAug 31, 2020 · antisense cardiovascular disease mergers and acquisitions Akcea Therapeutics. Ionis' headquarters (Ionis) Ionis Pharmaceuticals has struck a deal to buy its lipid disorder spinout Akcea...
DA: 82 PA: 20 MOZ Rank: 96
